MedTrace Logo

Study of CHS-114 in Participants With Advanced Solid Tumors

NCT05635643 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2026-03-19

No results posted yet for this study

Summary

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.

Conditions

Interventions

DRUG

CHS-114

CHS-114

DRUG

toripalimab

toripalimab-tpzi

Sponsors & Collaborators

  • Coherus Oncology, Inc.

    lead INDUSTRY

Principal Investigators

  • Koho Izuka, MD · Coherus BioSciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-12-15
Primary Completion
2026-09-30
Completion
2027-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05635643 on ClinicalTrials.gov